Commerzbank Aktiengesellschaft FI Boosts Position in Becton, Dickinson and Company $BDX

Commerzbank Aktiengesellschaft FI increased its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 24.9% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 12,155 shares of the medical instruments supplier’s stock after purchasing an additional 2,421 shares during the quarter. Commerzbank Aktiengesellschaft FI’s holdings in Becton, Dickinson and Company were worth $2,094,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the business. Saudi Central Bank acquired a new stake in shares of Becton, Dickinson and Company in the first quarter valued at approximately $26,000. Smallwood Wealth Investment Management LLC acquired a new stake in shares of Becton, Dickinson and Company in the first quarter valued at approximately $27,000. Alpine Bank Wealth Management acquired a new stake in shares of Becton, Dickinson and Company in the first quarter valued at approximately $29,000. Cornerstone Planning Group LLC boosted its holdings in shares of Becton, Dickinson and Company by 341.4% in the first quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier’s stock valued at $29,000 after acquiring an additional 99 shares during the period. Finally, Kelly Lawrence W & Associates Inc. CA acquired a new stake in shares of Becton, Dickinson and Company in the first quarter valued at approximately $31,000. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Insider Transactions at Becton, Dickinson and Company

In other news, EVP Michael David Garrison sold 1,185 shares of the stock in a transaction dated Friday, July 18th. The stock was sold at an average price of $180.29, for a total value of $213,643.65. Following the completion of the sale, the executive vice president owned 4,887 shares in the company, valued at approximately $881,077.23. This trade represents a 19.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Claire Fraser sold 917 shares of the stock in a transaction dated Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total value of $171,937.50. Following the completion of the sale, the director owned 22,226 shares of the company’s stock, valued at approximately $4,167,375. This trade represents a 3.96% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 3,023 shares of company stock worth $562,036. Company insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Stock Down 1.4%

Becton, Dickinson and Company stock opened at $186.41 on Friday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.62 and a current ratio of 1.10. The firm has a market capitalization of $53.43 billion, a price-to-earnings ratio of 33.53, a price-to-earnings-growth ratio of 1.48 and a beta of 0.25. Becton, Dickinson and Company has a fifty-two week low of $163.33 and a fifty-two week high of $251.99. The stock’s fifty day moving average is $190.07 and its two-hundred day moving average is $186.32.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share (EPS) for the quarter. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The business had revenue of $5.32 billion for the quarter. Analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 30th. Investors of record on Monday, September 8th were given a dividend of $1.04 per share. The ex-dividend date was Monday, September 8th. This represents a $4.16 annualized dividend and a yield of 2.2%. Becton, Dickinson and Company’s dividend payout ratio is 74.82%.

Wall Street Analysts Forecast Growth

BDX has been the subject of several analyst reports. Wells Fargo & Company upped their price target on Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an “equal weight” rating in a research note on Friday, August 8th. Wall Street Zen upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Saturday, August 9th. Royal Bank Of Canada initiated coverage on Becton, Dickinson and Company in a research note on Thursday, September 25th. They set a “sector perform” rating and a $211.00 price target for the company. Morgan Stanley upped their price target on Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an “overweight” rating in a research note on Monday, August 11th. Finally, Piper Sandler restated a “neutral” rating and set a $200.00 price target (up previously from $185.00) on shares of Becton, Dickinson and Company in a research note on Friday, August 8th. Three analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Becton, Dickinson and Company currently has a consensus rating of “Hold” and a consensus target price of $205.40.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.